-
Sector Analysis
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs. There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules,...
-
Sector Analysis
Anal Cancer (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Anal Cancer Marketed and Pipeline Drugs Market Overview Anal cancer develops in the cells and tissue of the skin lining on either the inside or outside of the anus. The development of anal cancer is directly linked to a complex inflammatory process secondary to infections such as (HPV) types 16 and 18. The progression of this inflammatory process heralds the development of anal intraepithelial neoplasia (AIN), or squamous cell carcinoma (SCC) in situ (Bowen disease), which is a pre-malignant condition....
-
Thematic Analysis
Digital Marketing Trends in Non-small Cell Lung Cancer
Digital Marketing Trends in Non-small Cell Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across Non-small Cell Lung Cancer (NSCLC) patient sites in the US from October 2022 to September 2023. This was followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com. Keytruda.com was also supported by the most paid search engine optimization (SEO) at over 7,600 keywords, closely followed by Enhertu.com and Opdivo.com. Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources. The Digital...
-
Sector Analysis
Multiple Myeloma Epidemiology Analysis and Forecast to 2032
Multiple Myeloma Epidemiology Analysis Report Overview In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma in 2022. The diagnosed incident cases of multiple myeloma are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate in...
-
Thematic Analysis
Digital Marketing Trends in Colorectal Cancer
Digital Marketing Trends in Colorectal Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across colorectal cancer (CRC) patient sites in the US. This was followed by Bristol Myers Squibb’s (BMS’s) Opdivo.com and Roche’s Avastin.com. Overall, the highest proportion of traffic to top branded patient CRC websites originated from direct sources, followed by organic sources. The Digital Marketing Trends in the Colorectal Cancer research report assesses key digital marketing metrics of pharma assets in CRC, including branded websites for patients...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market size in the 8MM was $2.3 billion in 2022. The market will grow at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The Acute Myeloid Leukemia market research report offers an overview of the epidemiology, symptoms, diagnosis, and disease management analysis. The report offers key topics covered including strategic...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market size for the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) was at $8.4 billion in 2022. The CLL market will register a CAGR of less than 1% from 2022 to 2032. The CLL market research report offers an overview of CLL, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet...
-
Sector Analysis
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Sector Analysis
Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Ewing Sarcoma Marketed and Pipeline Drugs Report Overview Ewing sarcoma (ES) is an aggressive tumor of adolescents and young adults that constitutes 10% to 15% of all bone sarcomas. The disease is named after James Ewing, who first described it in 1921. These sarcomas originate from unique mesenchymal progenitor cells due to their similar histologic and immunohistochemical characteristics. The most common anatomical sites include the pelvis, axial skeleton, and femur; however, it may occur in almost any bone or soft...
-
Sector Analysis
Next Generation Sequencing Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Next Generation Sequencing (NGS) Tests Market Report Overview The Next Generation Sequencing (NGS) tests market size was valued at $41.9 million in 2022. Next generation sequencing (NGS), or massively parallel sequencing, refers to high-throughput methods for DNA sequencing that are not Sanger-based, based on clonally amplified DNA templates or single DNA molecules rather than electrophoretic separation of chain-termination products produced in individual sequencing reactions. The following are some of the key highlights of the next generation sequencing market are: NGS...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.